Liver Diseases: Clinical Trials

1,428 trials for Liver Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

833 completed, 231 unknown, 113 terminated, 95 recruiting. 1428 Phase 3, 235 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 31428Completed 833, Unknown 231, Terminated 113, Recruiting 95, Active not recruiting 53, Withdrawn 52, Not yet recruiting 42, Enrolling by invitation 5, Suspended 4
Phase 2235Completed 105, Unknown 58, Recruiting 19, Not yet recruiting 15, Terminated 15, Withdrawn 12, Active not recruiting 7, Enrolling by invitation 2, Suspended 2

Follow Liver Diseases: new trials by email Literature Review of Liver Diseases trials Research Report on Liver Diseases

Trials (filtered) newest first · largest first

All 1,428 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Evaluating Mesenchymal Stem-Cell (MSC) Therapy in Non-viral Acute on Chronic Liver Failure (ACLF) Patients - Phase-III Trial
Umbilical cord Mesenchymal stem cell, Steroid, Standard Medical Treatment - Acute-On-Chronic Liver Failure
Phase 3Not yet recruitingInstitute of Liver and Biliary Sciences, India1002028-01-012025-08-17
Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D
Hepalatide 2.1mg, Placebo of Hepalatide - Hepatitis D, Chronic
Phase 3Not yet recruitingShanghai HEP Pharmaceutical Co., Ltd.1502027-06-012026-10-28
A Trial of Inebilizumab in Participants With Autoimmune Hepatitis
Inebilizumab, Placebo, Standard of Care - Autoimmune Hepatitis, AIH
Phase 3RecruitingAmgen1802026-12-182026-11-03
Personalized Adaptive Radiotherapy for Hepatocellular Carcinoma
Best Supportive Care (BSC), Personalized ultrafractionated stereotactic adaptive radiation therapy (PULSAR) - Hepatocellular Carcinoma (HCC)
Phase 3Not yet recruitingUniversity Health Network, Toronto602026-12-012026-10-26
Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis
Praziquantel 40 mg/kg per dose given once annually, Praziquantel 40 mg/kg given three times per year - Schistosomiasis, Schistosoma Mansoni
Phase 2 / Phase 3Not yet recruitingRhode Island Hospital6002026-11-012026-08-12
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
SHR-8068 + Adebrelimab + Bevacizumab, SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo, SHR-8068 Placebo + Adebrelimab + Bevacizumab - Hepatocellular Carcinoma
Phase 3Not yet recruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.6902026-11-012026-10-29
Evaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Placebo, Roflumilast - NAFLD (Nonalcoholic Fatty Liver Disease)
Phase 2 / Phase 3Not yet recruitingTanta University602026-11-012026-10-28
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Phase 3RecruitingRegeneron Pharmaceuticals15002026-10-282026-11-05
Evaluating the Safety and Efficacy of Rupatadine in the Treatment of Nonalcoholic Fatty Liver Disease Patients.
Placebo, Rupatadin - NAFLD (Nonalcoholic Fatty Liver Disease)
Phase 2 / Phase 3Not yet recruitingTanta University602026-10-252026-10-28
Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma
BGB-B2033, Lenvatinib, Sorafenib - Hepatocellular Carcinoma, Liver Cancer
Phase 3RecruitingBeOne Medicines4922026-10-232026-11-10
Study of BK1803 in Healthy Infants
BK1803, GOBIK Aqueous Suspension Syringes, Bimmugen® Injection - Pertussis, Diphtheria
Phase 3RecruitingTanabe Pharma Corporation3442026-10-212026-11-12
J-LINX: Japan LINerixibat eXtension Study
Linerixibat - Pruritus
Phase 3Not yet recruitingGlaxoSmithKline402026-10-092026-10-06
JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
JS207, JS007, Toripalimab - Hepatocellular Carcinoma
Phase 3Not yet recruitingShanghai Junshi Bioscience Co., Ltd.5602026-10-082026-09-16
Study Interchangeability Hep-B Vaccine Administered at Birth Dose
In-house Hepatitis B Vaccine, Registered Hepatitis B Vaccine - Vaccination Adverse Event, Immunogenicity, Vaccine
Phase 3Not yet recruitingPT Bio Farma2702026-10-012026-10-02
Treatment of CKD Patients With HCV
SOF+DCV, OBV/PTV/r) ± ribavirin (RBV) - HCV Infection ( Genotype 4) in CKD Patients
Phase 2 / Phase 3Not yet recruitingTanta University502026-09-152026-08-20
Misocholic Tablets for Non-Viral Elevated Liver Enzymes
Misocholic Tab, Placebo, Silymarin (Silybum marianum) - Alcohol-Related Liver Disease, Drug-Induced Liver Injury
Phase 3Not yet recruitingHanoi Medical University602026-09-152026-09-22
Efficacy of Diloxanide Furoate as Additional Luminal Agent Along With Metronidazole for the Treatment of Amoebic Liver Abscess
Diloxanide furoate, Placebo - Liver Abscess, Amoebic Liver Abscess
Phase 3Not yet recruitingPost Graduate Institute of Medical Education and Research, Chandigarh2202026-09-042026-09-10
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
TETA 4HCl formulation, D-Penicillamine - Wilson's Disease
Phase 3RecruitingOrphalan382026-09-032026-10-15
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
ZG005 for Injection, Bevacizumab ( Avastin), Sintilimab - Hepatocellular Carcinoma
Phase 3Not yet recruitingSuzhou Zelgen Biopharmaceuticals Co.,Ltd6002026-09-012026-09-10
A Study to Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)
PORT-77, Placebo - Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Phase 2 / Phase 3RecruitingPortal Therapeutics, Inc.2252026-09-012026-09-15

Showing 20 of 1428. Sign in to see all of them.

Narrower conditions

Carcinoma, Hepatocellular (317)  ·  Hepatitis C (284)  ·  Hepatitis C, Chronic (201)  ·  Hepatitis B (195)  ·  Liver Cirrhosis (98)  ·  Fibrosis (95)  ·  Liver Neoplasms (91)  ·  Non-alcoholic Fatty Liver Disease (90)  ·  Hepatitis B, Chronic (85)  ·  Diphtheria (57)  ·  Tetanus (56)  ·  Hepatitis (52)  ·  Haemophilus Infections (47)  ·  Liver Cirrhosis, Biliary (44)

Broader conditions

Digestive System Diseases (1413)  ·  Infections (687)  ·  Hepatitis (672)  ·  Hepatitis, Viral, Human (668)  ·  Virus Diseases (667)  ·  Blood-Borne Infections (651)  ·  Communicable Diseases (648)  ·  Pathological Conditions, Signs and Symptoms (571)  ·  Pathologic Processes (547)  ·  RNA Virus Infections (475)  ·  Flaviviridae Infections (389)  ·  Neoplasms by Site (357)  ·  Digestive System Neoplasms (354)  ·  Neoplasms (345)

Interventions

Ribavirin (202)  ·  peginterferon alfa-2a (104)  ·  peginterferon alfa-2b (62)  ·  Sorafenib (51)  ·  Sofosbuvir (49)  ·  Tenofovir (39)  ·  daclatasvir (32)  ·  ombitasvir (32)  ·  paritaprevir (30)  ·  glecaprevir and pibrentasvir (28)  ·  lenvatinib (28)  ·  dasabuvir (27)  ·  entecavir (26)  ·  Hepatitis B Vaccines (25)  ·  telaprevir (23)

Sponsors

GlaxoSmithKline (75)  ·  Merck Sharp & Dohme LLC (66)  ·  Gilead Sciences (60)  ·  Sun Yat-sen University (51)  ·  AbbVie (49)  ·  Bristol-Myers Squibb (46)  ·  Sanofi Pasteur, a Sanofi Company (25)  ·  Hoffmann-La Roche (23)  ·  Guangxi Medical University (22)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (16)  ·  Tanta University (14)  ·  Novartis Pharmaceuticals (13)  ·  Boehringer Ingelheim (12)  ·  French National Agency for Research on AIDS and Viral Hepatitis (11)  ·  Shanghai Zhongshan Hospital (11)

Countries

United States (392)  ·  China (298)  ·  France (231)  ·  Canada (215)  ·  Germany (203)  ·  Spain (194)  ·  Italy (186)  ·  United Kingdom (184)  ·  Australia (149)  ·  South Korea (148)  ·  Belgium (141)  ·  Taiwan (125)  ·  Poland (120)  ·  Puerto Rico (97)  ·  Japan (94)

Top investigators

Ming Shi, MD (12)

Results publications

PMID 30977945, PMID 30012435, PMID 30923816, PMID 31568620, PMID 29461687, PMID 30529905, PMID 29377566, PMID 29404492, PMID 12049862, PMID 28193518, PMID 11981766, PMID 25040192, PMID 25583164, PMID 27847279, PMID 30868245, PMID 35174470, PMID 37467180, PMID 37771546, PMID 37786277, PMID 12540794, PMID 19192962, PMID 21836029, PMID 25445400, PMID 26743093, PMID 26947564, PMID 27553375, PMID 32557715, PMID 36633470, PMID 36740893, PMID 37143199, PMID 37302573, PMID 40434633, PMID 40704461, PMID 10207464, PMID 12091661, PMID 16026887, PMID 17716936, PMID 18650514, PMID 19052126, PMID 19553649, PMID 20189674, PMID 20955704, PMID 22030902, PMID 22239511, PMID 22338037, PMID 22626609, PMID 23234725, PMID 23364953, PMID 23607593, PMID 23607594

NIH funding

2015 (25), 2014 (24), 2016 (16), 2023 (13), 2019 (10), 2004 (8), 2025 (8), 2008 (7), 2009 (7), 2017 (7), 2005 (5), 2018 (5), U01DK082843 (3), U01DK082864 (3), U01DK082871 (3)